Saturday 17 October 2026
Export RYTM’s income statement to Excel — free account
Rhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024. In the quarter to June 2026, revenue grew 46.9%, EPS grew 2.67% and free cash flow grew 60.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
86.17
1.80
−2.05%
Follow RYTM
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 4 | 3 | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z-Score |
15.89 | 3.76 | 5.31 | 4.61 | 3.57 | — | — | — | — | — |
P/S ratio |
36.66 | 26.24 | 33.62 | 63.15 | 156.95 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(5.58) | (9.07) | (6.41) | (1.46) | 3.15 | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/Operating CF |
(273.97) | (181.19) | (88.58) | (43.90) | (12.23) | — | — | — | — | — |
Beneish M-Score |
(2.93) | (4.25) | (1.47) | 3.25 | — | — | — | — | — | — |
P/B ratio |
50.02 | 157.14 | 15.33 | 5.65 | 1.74 | — | — | — | — | — |
Price to Tangible BV |
52.01 | 219.51 | 15.99 | 5.82 | 1.77 | — | — | — | — | — |
EV/Sales |
34.61 | 23.78 | 30.05 | 49.05 | 63.46 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
(56.77) | (27.17) | (17.09) | (6.69) | (1.37) | — | — | — | — | — |
EV/FCF |
(40.76) | (19.53) | (15.95) | (6.79) | (1.39) | — | — | — | — | — |
Quick Ratio |
3.92 | 2.94 | 5.27 | 8.53 | 6.81 | 9.60 | 11.98 | 18.56 | 22.04 | 2.23 |
Current Ratio |
4.41 | 3.24 | 5.58 | 8.90 | 7.10 | 10.10 | 12.39 | 19.05 | 22.42 | 2.36 |
Net Debt/EBITDA |
2.04 | 1.21 | 1.51 | 1.88 | 1.75 | 1.27 | 2.01 | 3.23 | 4.60 | 0.41 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.44 | 0.36 | 0.22 | 0.07 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.57 | 0.43 | 0.74 | 0.96 | 2.10 | 0.91 | 0.87 | 0.84 | 0.78 | 0.80 |
Capex/Depreciation |
(30.61) | (25.91) | (3.25) | (2.56) | 1.35 | (0.31) | (4.06) | (1.63) | (0.60) | (7.34) |
Interest Coverage |
(9.33) | (12.89) | (13.27) | (34.45) | (380.45) | (52.96) | (27.70) | (18.01) | (57.26) | (785.00) |
| (251.14%) | (276.33%) | (85.10%) | (66.05%) | (30.89%) | (59.88%) | (53.38%) | (37.88%) | (67.06%) | 142.86% | |
| (46.29%) | (72.98%) | (51.64%) | (50.88%) | (26.95%) | (54.07%) | (49.49%) | (35.96%) | (45.81%) | (117.20%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(55.77%) | (102.03%) | (72.59%) | (57.20%) | (26.00%) | (80.30%) | (49.96%) | (30.08%) | (25.96%) | (394.28%) |
Average Days of Receivables |
50.17 | 51.93 | 70.08 | 96.11 | 118.62 | — | — | — | — | — |
Research and Development Expense of Revenue |
88.19% | 182.87% | 174.29% | 459.56% | 3,301.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
102.73% | 110.90% | 151.80% | 389.34% | 2,171.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.01 | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
35.21% | 30.50% | 42.04% | 83.89% | 659.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.04 | 0.04 | 0.06 | 0.16 | 0.53 | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(2.91%) | (7.77%) | (7.09%) | (12.15%) | (13.33%) | — | — | — | — | — |
Free Cash Flow Yield |
(2.32%) | (4.64%) | (5.60%) | (11.44%) | (29.18%) | — | — | — | — | — |
Revenue per Share |
2.92 | 2.13 | 1.34 | 0.45 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.78) | (1.87) | (2.36) | (3.33) | (2.94) | (2.76) | (3.37) | (2.00) | (2.22) | (2.28) |
Capex per Share |
(0.63) | (0.66) | (0.10) | (0.08) | 0.03 | 0.00 | (0.09) | (0.02) | (0.01) | (0.10) |
Free Cash Flow per Share |
(2.41) | (2.53) | (2.46) | (3.41) | (2.91) | (2.77) | (3.46) | (2.02) | (2.23) | (2.38) |
Cash per Share |
5.99 | 5.26 | 4.78 | 6.39 | 5.94 | 3.92 | 8.03 | 8.13 | 11.16 | 1.03 |
Shareholders Equity per Share |
4.16 | 2.70 | 2.94 | 5.07 | 5.73 | 3.77 | 7.72 | 7.94 | 10.91 | 0.72 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.16 | 2.70 | 2.94 | 5.07 | 5.73 | 3.77 | 7.72 | 7.94 | 10.91 | 0.72 |
Free Cash Flow |
(156.63) | (154.38) | (141.87) | (177.71) | (144.44) | (122.19) | (126.13) | (62.78) | (29.59) | (24.28) |
Working Capital |
360.97 | 258.68 | 253.07 | 314.43 | 264.96 | 163.67 | 277.99 | 245.11 | 143.95 | 6.44 |
Capital Expenditures |
(40.95) | (40.50) | (5.71) | (4.28) | 1.57 | (0.21) | (3.38) | (0.72) | (0.13) | (1.06) |
Net Current Asset Value |
256.75 | 146.48 | 145.28 | 236.02 | 263.02 | 161.12 | 274.90 | 244.74 | 143.72 | 6.13 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.22 | 0.31 | 0.07 | 0.18 | (0.50) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.21 | 2.47 | 1.31 | 0.76 | 0.41 | 0.22 | 0.23 | 0.39 | 0.27 | 0.15 |
Cash ROIC |
(23.77%) | (31.82%) | (31.84%) | (29.74%) | (24.95%) | (36.01%) | (21.99%) | (12.60%) | (10.10%) | (136.12%) |
Accounts Receivable Turnover |
8.51 | 7.80 | 7.34 | 6.52 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
1.48 | 1.55 | 1.92 | 0.41 | 0.11 | 0.09 | 0.09 | 0.09 | 0.10 | 0.09 |
Inventory Turnover |
0.88 | 0.98 | 1.61 | 1.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
261.17 | 336.60 | 191.68 | 820.87 | 3,495.83 | 2,592.03 | 4,558.12 | 6,309.05 | 3,972.44 | 4,803.30 |
Days of Inventory on Hand |
482.24 | 511.70 | 338.40 | 499.16 | 67.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
22.30 | 16.69 | 10.55 | 3.62 | — | — | — | — | — | — |
Average Payables |
13.14 | 8.61 | 4.84 | 5.27 | 5.32 | 7.66 | 9.03 | 5.03 | 2.16 | 1.66 |
Average Inventory |
22.25 | 13.68 | 5.77 | 1.51 | — | — | — | — | — | — |
Average Assets |
436.23 | 362.51 | 357.61 | 356.00 | 258.30 | 247.80 | 284.37 | 205.97 | 82.04 | 24.81 |
Average Common Equity |
80.40 | 95.74 | 217.01 | 274.21 | 225.34 | 223.77 | 263.64 | 195.52 | 56.04 | (20.35) |
Columns are period end dates